论文部分内容阅读
应用免疫组化方法，对１０１例有８年随访结果的乳腺癌病例，进行了ｎｍ２３基因蛋白表达的检测。结果显示，ｎｍ２３基因蛋白表达与血行转移、淋巴结转移的发生呈负相关，与其它临床指标无关。生存率分析表明：ｎｍ２３基因高表达组患者的生存率明显高于低表达组（Ｐ＜０．０５）；腋淋巴结阴性组中，ｎｍ２３基因高、低表达的患者生存率差别显著，提示若将腋淋巴结阴性组中具有潜在转移危险性的ｎｍ２３低表达患者筛选出来，加强治疗，将会有助于提高生存率。应用Ｃｏｘ比例风险模型进行的多因素分析显示，ｎｍ２３基因表达与腋淋巴结转移、肿瘤大小均为乳腺癌的预后因素，其中ｎｍ２３基因高表达患者死亡的相对危险度较低表达患者低５４％。本研究结果提示，ｎｍ２３基因表达可以作为一项独立的预后指标，用以指导乳腺癌的临床治疗。
Immunohistochemistry was used to detect the expression of nm23 protein in 101 breast cancer patients with 8 years of follow-up. The results showed that the expression of nm23 protein was negatively correlated with the occurrence of hematogenous metastasis and lymph node metastasis, and was not related to other clinical indicators. The survival rate analysis showed that the survival rate of the patients with high expression of nm23 gene was significantly higher than that of patients with low expression (P<0.05). The survival rate of patients with high and low expression of nm23 gene was significantly different in the axillary lymph node negative group. Patients with low metastatic expression of nm23 with potential metastatic risk in the axillary lymph node-negative group were screened out and enhanced treatment would help improve survival. Multivariate analysis using the Cox proportional hazards model showed that nm23 gene expression and axillary lymph node metastasis and tumor size were both prognostic factors for breast cancer, and patients with high nm23 gene expression had a relatively low relative risk of death by 54%. The results of this study suggest that nm23 gene expression can be used as an independent prognostic indicator to guide the clinical treatment of breast cancer.